Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?

One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Novartis AG (NVS Quick QuoteNVS - Free Report) stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:

PE Ratio

A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.

On this front, Novartis has a trailing twelve months PE ratio of 17.0, as you can see in the chart below:



This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 21.3. If we focus on the long-term PE trend, Novartis’ current PE level puts it slightly below its midpoint over the past five years.



Further, the stock’s PE also compares favorably with the sector’s trailing twelve months PE ratio, which stands at 20.3. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.




We should also point out that Novartis has a forward PE ratio (price relative to this year’s earnings) of just 15.3, so it is fair to say that a slightly more value-oriented path may be ahead for Novartis stock in the near term too.

P/S Ratio

Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.

Right now, Novartis has a P/S ratio of about 3.8. This is a bit higher than the S&P 500 average, which comes in at 3.4 right now. Nonetheless, as we can see in the chart below, this is well below the highs for this stock in particular over the past few years.



If anything, NVS is more toward the lower end of its range in the time period from a P/S metric, suggesting some level of undervalued trading—at least compared to historical norms.

Broad Value Outlook

In aggregate, Novartis currently has a Zacks Value Style Score of B, putting it into the top 40% of all stocks we cover from this look. This makes Novartis a solid choice for value investors, and some of its other key metrics make this pretty clear too.

For example, the PEG ratio for Novartis is just 1.9, a level that is lower than the industry average of 2.1. The PEG ratio is a modified PE ratio that takes into account the stock’s earnings growth rate. Additionally, its P/CF ratio (another great indicator of value) comes in at 10.7, which is better than the industry average of 12.4. Clearly, NVS is a solid choice on the value front from multiple angles.

What About the Stock Overall?

Though Novartis might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth grade of C and a Momentum score of D. This gives NVS a Zacks VGM score—or its overarching fundamental grade—of C. (You can read more about the Zacks Style Scores here >>)

Meanwhile, the company’s recent earnings estimates have been encouraging. The current year has seen four estimates go higher in the past sixty days compared to none lower, while the next year estimate has seen two upward and zero downward revisions in the same time period.

This has had a meaningful impact on the consensus estimate as the current year consensus estimate has risen by 2.3% in the past two months, while the next year estimate has increased 1.1%. You can see the consensus estimate trend and recent price action for the stock in the chart below:

Even though Novartis has a better estimates trend, the stock has just a Zacks Rank #3 (Hold). That is why we are looking for in-line performance from the company in the near term.

Bottom Line

Novartis is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. Furthermore, a robust industry rank (among the Top 17%) should boost investor confidence.

However over the past two years, the industry has underperformed the broader market, as you can see below:




Despite the poor past performance of the industry, a good industry rank signals that the stock is likely to benefit from favorable broader factors in the immediate future. Add to this the positive estimate revisions and robust value metrics, and we believe that we have a strong value contender in Novartis.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>